niacin has been researched along with Schizophrenia in 98 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niacin sensitivity and efficacy were reduced in schizophrenia." | 9.14 | Niacin sensitivity and the arachidonic acid pathway in schizophrenia. ( Hoffman, WF; Messamore, E; Yao, JK, 2010) |
| "Patients with schizophrenia have in different studies shown reduced niacin sensitivity and lower electrodermal activity (EDA) after auditory stimulation." | 9.12 | Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. ( Hultman, CM; Nilsson, BM; Wiesel, FA, 2006) |
| "Niacin skin flush test is a simple, non-invasive and easily replicable method in the research of schizophrenia." | 8.86 | Niacin skin flush test: a research tool for studying schizophrenia. ( Buretić-Tomljanović, A; Gudelj, L; Nadalin, S; Rubesa, G; Tomljanović, D, 2010) |
| "Oral niacin administration was sensitive to the detection of ASRN in schizophrenia." | 8.31 | Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route ( Bonet, J; Carena, F; Martino, P; Vera, CF, 2023) |
| "In this case-control study, niacin skin-flushing tests were conducted in 613 patients (including 307 schizophrenia patients, 179 bipolar disorder patients, and 127 unipolar depression patients) and 148 healthy controls (HCs) with a modified method." | 8.02 | Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker. ( Cui, GP; Gao, Y; Guan, LL; Hu, XW; Ji, F; Jiang, J; Li, J; Li, MH; Li, ZZ; Qing, Y; Sun, LY; Wan, CL; Wang, DD; Wang, JJ; Wang, PK; Yang, XH; Zhang, J; Zhang, TH; Zhuang, Y, 2021) |
| "The available data suggest that abnormalities of arachidonic acid-related signaling may be of relevance in attenuated niacin-induced flush responses and lipid and glucose metabolism disturbances, which are all common among individuals with schizophrenia." | 7.96 | An association between niacin skin flush response and plasma triglyceride levels in patients with schizophrenia. ( Buretić-Tomljanović, A; Jonovska, S; Nadalin, S; Šendula Jengić, V, 2020) |
| " Given this gene's role in niacin metabolism and the evidence for niacin deficiency provoking schizophrenialike symptoms in neuropsychiatric diseases such as pellagra and Hartnup disease, these results suggest that the rs10866912 genotype and niacin status may have implications for schizophrenia susceptibility and treatment." | 7.91 | Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. ( Bakshi, A; Brown, MA; Filippich, C; Fowdar, J; Giacomotto, J; Gratten, J; Gundugurti, PR; Hemani, G; Holliday, EG; Jegadeesan, J; John, S; Jorde, LB; McLean, D; McRae, A; Mowry, BJ; Nagasundaram, A; Nancarrow, D; Nertney, D; Nyholt, DR; Padmavati, R; Patel, K; Periyasamy, S; Rajendren, P; Selvaraj, K; Smith, H; Suetani, R; Thara, R; Thirunavukkarasu, P; Tirupati, S; Vinkhuyzen, A; Wray, NR, 2019) |
| " In this study, we employed the niacin skin-flushing test in Chinese population and confirmed a niacin-blunted subgroup of SZ patients distinguishable from mood disorders (MD) and normal individuals." | 7.88 | Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population. ( Cai, C; He, L; Hu, X; Jiang, J; Qing, Y; Sun, L; Wan, C; Wang, D; Wang, J; Wang, P; Yang, C; Yang, P; Yang, T; Yang, X; Zhang, J, 2018) |
| "The skin flush response to niacin is abnormally blunted among a subset of patients with schizophrenia (SZ), preferentially associates with SZ compared to other mental illnesses, occurs frequently in nonpsychotic members of SZ-affected families, appears heritable, and shows evidence of genetic association." | 7.83 | Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia. ( Condray, R; Dougherty, GG; Gautier, CH; Gurklis, JA; Haas, GL; Kasckow, JW; Kisslinger, BL; Messamore, E; Yao, JK, 2016) |
| "We hypothesized that attenuated niacin skin flushing in schizophrenia patients might be associated with polymorphic variants in PLA2G6 and PLA2G4C genes (rs4375 and rs1549637 variations) which encode calcium-independent phospholipase A2 beta (iPLA2β) and cytosolic phospholipase A2 gamma (cPLA2γ) enzymes." | 7.81 | Polymorphisms in PLA2G6 and PLA2G4C genes for calcium-independent phospholipase A2 do not contribute to attenuated niacin skin flush response in schizophrenia patients. ( Buretić-Tomljanović, A; Nadalin, S; Radović, I, 2015) |
| "Schizophrenia patients frequently display reduced niacin flush responses, and similar characteristics are also observed in their nonpsychotic relatives." | 7.79 | A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. ( Chen, WJ; Faraone, SV; Huang, SS; Hwu, HG; Lien, YJ; Liu, CM; Tsuang, MT, 2013) |
| "We investigated the etiology of the attenuated niacin skin flush response in schizophrenia patients." | 7.79 | The impact of PLA2G4A and PTGS2 gene polymorphisms, and red blood cell PUFAs deficit on niacin skin flush response in schizophrenia patients. ( Buretić-Tomljanović, A; Giacometti, J; Jonovska, S; Nadalin, S; Tomljanović, D, 2013) |
| "Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia." | 7.78 | Niacin subsensitivity is associated with functional impairment in schizophrenia. ( Messamore, E, 2012) |
| " Osmond enunciated the adrenochrome hypothesis for the biogenesis of schizophrenia in 1952, slightly later proposing and, apparently, demonstrating, in a double-blind study, that the symptoms of the illness could be reversed by administering large doses of niacin." | 7.76 | Hallucinogens as hard science: the adrenochrome hypothesis for the biogenesis of schizophrenia. ( Mills, JA, 2010) |
| "We previously reported familial aggregation in flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives." | 7.75 | Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. ( Chang, SS; Chen, WJ; Guo, SC; Hsieh, MH; Hwang, TJ; Hwu, HG; Lin, SH; Liu, CM; Liu, SK, 2009) |
| "The pathway for de novo synthesis of the suite of niacin congeners, the kynurenine pathway, has been shown to be upregulated in prior studies of postmortem brain tissue from individuals with schizophrenia." | 7.74 | The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. ( Dulay, JR; Miller, CL, 2008) |
| "This study investigated the differences in niacin skin flush responses between patients with schizophrenia, bipolar mania, and normal controls." | 7.74 | Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. ( Chang, SS; Chen, WJ; Hwang, TJ; Hwu, HG; Liao, SC; Liu, CM; Liu, SK; Shieh, MH, 2007) |
| "While our results indicate niacin hyposensitivity as reliable biological marker in schizophrenia, they do not provide clear evidence for its heritability." | 7.74 | Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. ( Blanz, B; Gerhard, UJ; Grunwald, S; Klemm, S; Rosburg, T; Sauer, H; Smesny, S; Stockebrand, M, 2007) |
| "Niacin (vitamin B3) flushing--a marker of altered prostaglandin signaling--is indirectly linked to the phospholipid-prostaglandin metabolism." | 7.73 | Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. ( Baur, K; Berger, G; Riemann, S; Rosburg, T; Rudolph, N; Sauer, H; Smesny, S, 2005) |
| "We describe a case of massive oral niacin overdose that resulted in severe persistent hypotension without the manifestation of cutaneous flushing." | 7.73 | Treatment advice on the internet leads to a life-threatening adverse reaction: hypotension associated with Niacin overdose. ( Bizovi, KE; Grazer, RE; Mularski, RA; Santoni, L; Strother, JS, 2006) |
| "This study compares the skin reactions to the niacin flushing test of 16 schizophrenic patients with those of 17 depressed patients and 16 healthy controls." | 7.73 | Niacin skin flushing in schizophrenic and depressed patients and healthy controls. ( Bosveld-van Haandel, L; Kluiter, H; Knegtering, R; van den Bosch, RJ, 2006) |
| "Niacin response was absent in 23% of the schizophrenic patients and in 14% in controls (n." | 5.32 | Increased phospholipase A2 activity in schizophrenia with absent response to niacin. ( Barbosa, NR; Gattaz, WF; Talib, LL; Tavares, H; Yacubian, J, 2003) |
| " We address this question in the present study by characterizing the dose-response relationship between topically applied alpha-methylnicotinate (AMN) and cutaneous blood flow changes, which were quantified by laser Doppler flowmetry." | 5.32 | The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. ( Hoffman, WF; Janowsky, A; Messamore, E, 2003) |
| "(2) Patients with schizophrenia have previously been reported to show a reduced flushing response." | 5.31 | A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. ( Easton, T; Hirsch, SR; Puri, BK; Richardson, AJ, 2002) |
| "Niacin sensitivity and efficacy were reduced in schizophrenia." | 5.14 | Niacin sensitivity and the arachidonic acid pathway in schizophrenia. ( Hoffman, WF; Messamore, E; Yao, JK, 2010) |
| "Patients with schizophrenia have in different studies shown reduced niacin sensitivity and lower electrodermal activity (EDA) after auditory stimulation." | 5.12 | Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. ( Hultman, CM; Nilsson, BM; Wiesel, FA, 2006) |
| "After reviewing the literature on nicotinic acid in the treatment of schizophrenia, the authors present the results of the Canadian collaborative study." | 5.04 | Nicotinic acid in the treatment of schizophrenias. Practical and theoretical considerations. ( Ban, TA, 1975) |
| "Niacin skin flush test is a simple, non-invasive and easily replicable method in the research of schizophrenia." | 4.86 | Niacin skin flush test: a research tool for studying schizophrenia. ( Buretić-Tomljanović, A; Gudelj, L; Nadalin, S; Rubesa, G; Tomljanović, D, 2010) |
| "Oral niacin administration was sensitive to the detection of ASRN in schizophrenia." | 4.31 | Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route ( Bonet, J; Carena, F; Martino, P; Vera, CF, 2023) |
| "Impaired sensitivity of the skin flush response to niacin is found in approximately 30% of patients with schizophrenia." | 4.12 | Replication of the abnormal niacin response in first episode psychosis measured using laser Doppler flowmeter. ( Chen, T; Gan, R; Hu, Y; Liu, H; Liu, X; Tang, X; Wang, J; Wei, Y; Wu, G; Xu, L; Zeng, J; Zhang, T; Zhao, Y, 2022) |
| "In this case-control study, niacin skin-flushing tests were conducted in 613 patients (including 307 schizophrenia patients, 179 bipolar disorder patients, and 127 unipolar depression patients) and 148 healthy controls (HCs) with a modified method." | 4.02 | Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker. ( Cui, GP; Gao, Y; Guan, LL; Hu, XW; Ji, F; Jiang, J; Li, J; Li, MH; Li, ZZ; Qing, Y; Sun, LY; Wan, CL; Wang, DD; Wang, JJ; Wang, PK; Yang, XH; Zhang, J; Zhang, TH; Zhuang, Y, 2021) |
| "The available data suggest that abnormalities of arachidonic acid-related signaling may be of relevance in attenuated niacin-induced flush responses and lipid and glucose metabolism disturbances, which are all common among individuals with schizophrenia." | 3.96 | An association between niacin skin flush response and plasma triglyceride levels in patients with schizophrenia. ( Buretić-Tomljanović, A; Jonovska, S; Nadalin, S; Šendula Jengić, V, 2020) |
| " Given this gene's role in niacin metabolism and the evidence for niacin deficiency provoking schizophrenialike symptoms in neuropsychiatric diseases such as pellagra and Hartnup disease, these results suggest that the rs10866912 genotype and niacin status may have implications for schizophrenia susceptibility and treatment." | 3.91 | Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. ( Bakshi, A; Brown, MA; Filippich, C; Fowdar, J; Giacomotto, J; Gratten, J; Gundugurti, PR; Hemani, G; Holliday, EG; Jegadeesan, J; John, S; Jorde, LB; McLean, D; McRae, A; Mowry, BJ; Nagasundaram, A; Nancarrow, D; Nertney, D; Nyholt, DR; Padmavati, R; Patel, K; Periyasamy, S; Rajendren, P; Selvaraj, K; Smith, H; Suetani, R; Thara, R; Thirunavukkarasu, P; Tirupati, S; Vinkhuyzen, A; Wray, NR, 2019) |
| " In this study, we employed the niacin skin-flushing test in Chinese population and confirmed a niacin-blunted subgroup of SZ patients distinguishable from mood disorders (MD) and normal individuals." | 3.88 | Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population. ( Cai, C; He, L; Hu, X; Jiang, J; Qing, Y; Sun, L; Wan, C; Wang, D; Wang, J; Wang, P; Yang, C; Yang, P; Yang, T; Yang, X; Zhang, J, 2018) |
| "The skin flush response to niacin is abnormally blunted among a subset of patients with schizophrenia (SZ), preferentially associates with SZ compared to other mental illnesses, occurs frequently in nonpsychotic members of SZ-affected families, appears heritable, and shows evidence of genetic association." | 3.83 | Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia. ( Condray, R; Dougherty, GG; Gautier, CH; Gurklis, JA; Haas, GL; Kasckow, JW; Kisslinger, BL; Messamore, E; Yao, JK, 2016) |
| "We hypothesized that attenuated niacin skin flushing in schizophrenia patients might be associated with polymorphic variants in PLA2G6 and PLA2G4C genes (rs4375 and rs1549637 variations) which encode calcium-independent phospholipase A2 beta (iPLA2β) and cytosolic phospholipase A2 gamma (cPLA2γ) enzymes." | 3.81 | Polymorphisms in PLA2G6 and PLA2G4C genes for calcium-independent phospholipase A2 do not contribute to attenuated niacin skin flush response in schizophrenia patients. ( Buretić-Tomljanović, A; Nadalin, S; Radović, I, 2015) |
| "We investigated the etiology of the attenuated niacin skin flush response in schizophrenia patients." | 3.79 | The impact of PLA2G4A and PTGS2 gene polymorphisms, and red blood cell PUFAs deficit on niacin skin flush response in schizophrenia patients. ( Buretić-Tomljanović, A; Giacometti, J; Jonovska, S; Nadalin, S; Tomljanović, D, 2013) |
| "Schizophrenia patients frequently display reduced niacin flush responses, and similar characteristics are also observed in their nonpsychotic relatives." | 3.79 | A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. ( Chen, WJ; Faraone, SV; Huang, SS; Hwu, HG; Lien, YJ; Liu, CM; Tsuang, MT, 2013) |
| "Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia." | 3.78 | Niacin subsensitivity is associated with functional impairment in schizophrenia. ( Messamore, E, 2012) |
| " Osmond enunciated the adrenochrome hypothesis for the biogenesis of schizophrenia in 1952, slightly later proposing and, apparently, demonstrating, in a double-blind study, that the symptoms of the illness could be reversed by administering large doses of niacin." | 3.76 | Hallucinogens as hard science: the adrenochrome hypothesis for the biogenesis of schizophrenia. ( Mills, JA, 2010) |
| "We previously reported familial aggregation in flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives." | 3.75 | Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. ( Chang, SS; Chen, WJ; Guo, SC; Hsieh, MH; Hwang, TJ; Hwu, HG; Lin, SH; Liu, CM; Liu, SK, 2009) |
| "The pathway for de novo synthesis of the suite of niacin congeners, the kynurenine pathway, has been shown to be upregulated in prior studies of postmortem brain tissue from individuals with schizophrenia." | 3.74 | The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. ( Dulay, JR; Miller, CL, 2008) |
| "Though a reduced flush response to niacin has been found in schizophrenic patients, whether it is a vulnerability indicator to schizophrenia remains little known." | 3.74 | Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. ( Chang, SS; Chen, WJ; Guo, SC; Hsieh, MH; Hwang, TJ; Hwu, HG; Lin, SH; Liu, CM; Liu, SK, 2007) |
| "This study investigated the differences in niacin skin flush responses between patients with schizophrenia, bipolar mania, and normal controls." | 3.74 | Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. ( Chang, SS; Chen, WJ; Hwang, TJ; Hwu, HG; Liao, SC; Liu, CM; Liu, SK; Shieh, MH, 2007) |
| "While our results indicate niacin hyposensitivity as reliable biological marker in schizophrenia, they do not provide clear evidence for its heritability." | 3.74 | Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. ( Blanz, B; Gerhard, UJ; Grunwald, S; Klemm, S; Rosburg, T; Sauer, H; Smesny, S; Stockebrand, M, 2007) |
| "Niacin (vitamin B3) flushing--a marker of altered prostaglandin signaling--is indirectly linked to the phospholipid-prostaglandin metabolism." | 3.73 | Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. ( Baur, K; Berger, G; Riemann, S; Rosburg, T; Rudolph, N; Sauer, H; Smesny, S, 2005) |
| "We describe a case of massive oral niacin overdose that resulted in severe persistent hypotension without the manifestation of cutaneous flushing." | 3.73 | Treatment advice on the internet leads to a life-threatening adverse reaction: hypotension associated with Niacin overdose. ( Bizovi, KE; Grazer, RE; Mularski, RA; Santoni, L; Strother, JS, 2006) |
| "This study compares the skin reactions to the niacin flushing test of 16 schizophrenic patients with those of 17 depressed patients and 16 healthy controls." | 3.73 | Niacin skin flushing in schizophrenic and depressed patients and healthy controls. ( Bosveld-van Haandel, L; Kluiter, H; Knegtering, R; van den Bosch, RJ, 2006) |
| "Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA." | 3.71 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001) |
| " We examined the familial co-distribution of two abnormalities common in schizophrenia: impaired auditory sensory gating and impaired flush response to niacin." | 3.70 | Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. ( Waldo, MC, 1999) |
| "Schizophrenia is a devastating and poorly understood disease for which the only accepted therapy is nonspecific antipsychotic and anti-seizure medication." | 2.44 | Vitamin therapy in schizophrenia. ( Hoffer, LJ, 2008) |
| "Inflammation is a risk factor for the onset and progression of schizophrenia, and dietary factors are related to chronic inflammation." | 1.62 | Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea. ( Cha, HY; Kim, SW; Yang, SJ, 2021) |
| "Niacin response was absent in 23% of the schizophrenic patients and in 14% in controls (n." | 1.32 | Increased phospholipase A2 activity in schizophrenia with absent response to niacin. ( Barbosa, NR; Gattaz, WF; Talib, LL; Tavares, H; Yacubian, J, 2003) |
| " We address this question in the present study by characterizing the dose-response relationship between topically applied alpha-methylnicotinate (AMN) and cutaneous blood flow changes, which were quantified by laser Doppler flowmetry." | 1.32 | The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. ( Hoffman, WF; Janowsky, A; Messamore, E, 2003) |
| "(2) Patients with schizophrenia have previously been reported to show a reduced flushing response." | 1.31 | A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. ( Easton, T; Hirsch, SR; Puri, BK; Richardson, AJ, 2002) |
| "Pellagra was once a major cause of three behaviorally different mental disorders-schizophreniform, manic-depressive-like, and phobic neurotic - plus drying dermatoses, autonomic neuropathies, tinnitus, and fatigue." | 1.26 | The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. ( Rudin, DO, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (44.90) | 18.7374 |
| 1990's | 8 (8.16) | 18.2507 |
| 2000's | 22 (22.45) | 29.6817 |
| 2010's | 16 (16.33) | 24.3611 |
| 2020's | 8 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Gan, R | 2 |
| Zhao, Y | 1 |
| Wu, G | 2 |
| Zeng, J | 1 |
| Hu, Y | 2 |
| Xu, L | 2 |
| Wei, Y | 2 |
| Tang, X | 2 |
| Liu, X | 1 |
| Liu, H | 1 |
| Chen, T | 2 |
| Wang, J | 3 |
| Zhang, T | 2 |
| Carena, F | 1 |
| Martino, P | 1 |
| Vera, CF | 1 |
| Bonet, J | 1 |
| Fuller-Thomson, E | 1 |
| Mehta, R | 1 |
| Nadalin, S | 5 |
| Jonovska, S | 2 |
| Šendula Jengić, V | 1 |
| Buretić-Tomljanović, A | 5 |
| Wang, DD | 1 |
| Hu, XW | 1 |
| Jiang, J | 2 |
| Sun, LY | 1 |
| Qing, Y | 2 |
| Yang, XH | 1 |
| Gao, Y | 1 |
| Cui, GP | 1 |
| Li, MH | 1 |
| Wang, PK | 1 |
| Zhang, J | 2 |
| Zhuang, Y | 1 |
| Li, ZZ | 1 |
| Li, J | 1 |
| Guan, LL | 1 |
| Zhang, TH | 1 |
| Wang, JJ | 1 |
| Ji, F | 1 |
| Wan, CL | 1 |
| Cui, H | 1 |
| Hui, L | 1 |
| Tang, Y | 1 |
| Li, C | 1 |
| Wan, C | 2 |
| Cha, HY | 1 |
| Yang, SJ | 2 |
| Kim, SW | 2 |
| Messamore, E | 6 |
| Kim, EJ | 1 |
| Lim, SY | 1 |
| Lee, HJ | 1 |
| Lee, JY | 1 |
| Choi, S | 1 |
| Kim, SY | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Yoon, JS | 1 |
| Sun, L | 1 |
| Yang, X | 1 |
| Hu, X | 1 |
| Wang, D | 1 |
| Yang, T | 1 |
| Yang, C | 1 |
| Yang, P | 1 |
| Wang, P | 1 |
| Cai, C | 1 |
| He, L | 1 |
| Nimgaonkar, VL | 1 |
| Wood, J | 1 |
| Deshpande, S | 1 |
| Periyasamy, S | 1 |
| John, S | 1 |
| Padmavati, R | 1 |
| Rajendren, P | 1 |
| Thirunavukkarasu, P | 1 |
| Gratten, J | 1 |
| Vinkhuyzen, A | 1 |
| McRae, A | 1 |
| Holliday, EG | 1 |
| Nyholt, DR | 1 |
| Nancarrow, D | 1 |
| Bakshi, A | 1 |
| Hemani, G | 1 |
| Nertney, D | 1 |
| Smith, H | 1 |
| Filippich, C | 1 |
| Patel, K | 1 |
| Fowdar, J | 1 |
| McLean, D | 1 |
| Tirupati, S | 1 |
| Nagasundaram, A | 1 |
| Gundugurti, PR | 1 |
| Selvaraj, K | 1 |
| Jegadeesan, J | 1 |
| Jorde, LB | 1 |
| Wray, NR | 1 |
| Brown, MA | 1 |
| Suetani, R | 1 |
| Giacomotto, J | 1 |
| Thara, R | 1 |
| Mowry, BJ | 1 |
| Nilsson, BM | 2 |
| Holm, G | 1 |
| Hultman, CM | 2 |
| Ekselius, L | 1 |
| Xu, XJ | 1 |
| Jiang, GS | 1 |
| Radović, I | 1 |
| Durmaz, O | 1 |
| Yao, JK | 2 |
| Dougherty, GG | 1 |
| Gautier, CH | 1 |
| Haas, GL | 1 |
| Condray, R | 1 |
| Kasckow, JW | 1 |
| Kisslinger, BL | 1 |
| Gurklis, JA | 1 |
| Hoffer, LJ | 1 |
| Miller, CL | 1 |
| Dulay, JR | 1 |
| Giacometti, J | 2 |
| Rubesa, G | 2 |
| Vulin, M | 1 |
| Tomljanović, D | 3 |
| Gudelj, L | 1 |
| Hoffman, WF | 2 |
| Mills, JA | 1 |
| Lien, YJ | 1 |
| Huang, SS | 1 |
| Liu, CM | 4 |
| Hwu, HG | 4 |
| Faraone, SV | 1 |
| Tsuang, MT | 1 |
| Chen, WJ | 4 |
| Tavares, H | 1 |
| Yacubian, J | 1 |
| Talib, LL | 1 |
| Barbosa, NR | 1 |
| Gattaz, WF | 1 |
| Janowsky, A | 1 |
| VERRIENTI, G | 1 |
| BELSANTI, R | 2 |
| MARZI, F | 1 |
| BENNETT, IF | 1 |
| COHEN, D | 1 |
| STARER, E | 1 |
| SCHERER, IW | 1 |
| WINNE, JF | 1 |
| PENA, CD | 1 |
| WIEDORN, WS | 1 |
| ERVIN, F | 1 |
| MACKINNON, IH | 1 |
| MICHAEL, ST | 1 |
| POLATIN, P | 1 |
| KNOBEL, M | 2 |
| CAMPOS, MR | 2 |
| CELLERINO, RJ | 2 |
| FRIDMAN, M | 1 |
| WEISBERG, MM | 2 |
| FRIDMAN, MC | 1 |
| HOFFER, A | 6 |
| CALLBECK, MJ | 1 |
| BANERJEE, S | 1 |
| AGARWAL, PS | 1 |
| HOSHINO, A | 1 |
| CEASE, EA | 1 |
| LAUER, JW | 1 |
| INSKIP, WM | 1 |
| BERNSOHN, J | 1 |
| ZELLER, EA | 1 |
| RESNICK, O | 1 |
| WOLFE, JM | 1 |
| FREEMAN, H | 1 |
| ELMADJIAN, F | 1 |
| FREYMUTH, HW | 1 |
| WALLER, H | 1 |
| BAUMECKER, P | 1 |
| STEIN, H | 1 |
| ENGLISH, DC | 1 |
| KASSAY, G | 3 |
| REINHARDT, RF | 1 |
| SCHIFF, SB | 1 |
| SINNETT, ER | 1 |
| ASHBY, WR | 1 |
| COLLINS, GH | 1 |
| BASSETT, M | 1 |
| DENSON, R | 1 |
| Osmond, H | 3 |
| PETROVA, AG | 1 |
| HEYMAN, JJ | 1 |
| HALPERN, S | 1 |
| MERLIS, S | 1 |
| MATHE, V | 2 |
| GAMNA, G | 1 |
| FORNARI, U | 1 |
| O'REILLY, PO | 1 |
| KASHSHAI, D | 1 |
| MATE, B | 1 |
| Ross, BM | 3 |
| Smesny, S | 4 |
| Rosburg, T | 3 |
| Riemann, S | 1 |
| Baur, K | 2 |
| Rudolph, N | 2 |
| Berger, G | 1 |
| Sauer, H | 3 |
| Mularski, RA | 1 |
| Grazer, RE | 1 |
| Santoni, L | 1 |
| Strother, JS | 1 |
| Bizovi, KE | 1 |
| Law, MH | 1 |
| Cotton, RG | 1 |
| Berger, GE | 1 |
| Wiesel, FA | 1 |
| Bosveld-van Haandel, L | 1 |
| Knegtering, R | 1 |
| Kluiter, H | 1 |
| van den Bosch, RJ | 1 |
| Lin, SH | 2 |
| Chang, SS | 3 |
| Liu, SK | 3 |
| Hwang, TJ | 3 |
| Hsieh, MH | 2 |
| Guo, SC | 2 |
| Liao, SC | 1 |
| Shieh, MH | 1 |
| Puri, BK | 2 |
| Richardson, AJ | 2 |
| Counsell, SJ | 1 |
| Ward, PE | 1 |
| Bustos, MG | 1 |
| Hamilton, G | 1 |
| Bhakoo, KK | 1 |
| Treasaden, IH | 1 |
| Klemm, S | 1 |
| Stockebrand, M | 1 |
| Grunwald, S | 1 |
| Gerhard, UJ | 1 |
| Blanz, B | 1 |
| Li, W | 1 |
| Tao, R | 1 |
| Zhang, X | 1 |
| Ju, G | 1 |
| Shi, J | 1 |
| Liu, S | 1 |
| Wang, Z | 1 |
| Jin, S | 1 |
| Guo, Y | 1 |
| Wei, J | 1 |
| Petrie, WM | 1 |
| Ban, TA | 3 |
| Ananth, JV | 1 |
| Elgart, ML | 1 |
| Glen, AI | 1 |
| Cooper, SJ | 1 |
| Rybakowski, J | 2 |
| Vaddadi, K | 1 |
| Brayshaw, N | 1 |
| Horrobin, DF | 2 |
| Lin, A | 2 |
| Hudson, CJ | 2 |
| Cogan, S | 1 |
| Cashman, F | 1 |
| Warsh, JJ | 1 |
| Hudson, C | 1 |
| Gotowiec, A | 1 |
| Seeman, M | 2 |
| Warsh, J | 1 |
| Waldo, MC | 1 |
| Turenne, SD | 1 |
| Hirsch, SR | 1 |
| Easton, T | 1 |
| Goumeniouk, AD | 1 |
| Ancill, RJ | 1 |
| MacEwan, GW | 1 |
| Koczapski, AB | 1 |
| Weterle, R | 1 |
| Wilson, DW | 1 |
| Douglass, AB | 1 |
| Fiedler, P | 1 |
| Wolkin, A | 1 |
| Rotrosen, J | 1 |
| Gama Marques, J | 1 |
| Bender, DA | 1 |
| Rudin, DO | 1 |
| Pfeiffer, CC | 1 |
| Dickerson, JW | 1 |
| Wiryanti, J | 1 |
| Abou-Saleh, MT | 1 |
| Coppen, A | 1 |
| Shah, DR | 1 |
| Pandey, SK | 1 |
| Rathi, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Topical Niacin Skin Flush Test: A Means for Longitudinal Monitoring of Two Different Biological Subgroups of Patients With First Episode Psychosis[NCT01324297] | 107 participants (Actual) | Observational | 2011-12-31 | Terminated (stopped due to Unable to secure funding for second phase of study (i.e., niacin skin flush test in early psychosis patients).) | |||
| The Role of Tryptophan on Aryl Hydrocarbon Receptor Activation: a Randomized, Double Blind, Placebo-controlled, Crossover Design Pilot Trial[NCT03059862] | 20 participants (Actual) | Interventional | 2017-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for niacin and Schizophrenia
| Article | Year |
|---|---|
The niacin response biomarker as a schizophrenia endophenotype: A status update.
Topics: Endophenotypes; Erythema; Humans; Niacin; Precision Medicine; Schizophrenia | 2018 |
Niacin-respondent subset of schizophrenia – a therapeutic review.
Topics: Humans; Niacin; Psychotic Disorders; Schizophrenia; Treatment Outcome; Vitamin B Complex | 2015 |
Vitamin therapy in schizophrenia.
Topics: Ascorbic Acid; Avitaminosis; Folic Acid; Humans; Niacin; Schizophrenia; Vitamins | 2008 |
Phospholipid membrane abnormalities and reduced niacin skin flush response in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Arachidonic Acid; Biomarkers; Brain; Docosahexaenoic Acids; | 2008 |
Niacin skin flush test: a research tool for studying schizophrenia.
Topics: Administration, Cutaneous; Administration, Oral; Arachidonic Acid; Biomarkers; Brain; Docosahexaenoi | 2010 |
Relationship between the niacin skin flush response and essential fatty acids in schizophrenia.
Topics: Arachidonic Acid; Fatty Acids, Essential; Flushing; Humans; Niacin; Nicotinic Acids; Schizophrenia; | 2003 |
Prostaglandin-mediated signaling in schizophrenia.
Topics: Animals; Humans; Niacin; Phospholipids; Prostaglandins; Schizophrenia; Signal Transduction; Skin | 2004 |
The role of phospholipases A2 in schizophrenia.
Topics: Antipsychotic Agents; Arachidonic Acid; Humans; Niacin; Phospholipases A; Phospholipases A2; Schizop | 2006 |
The niacin challenge test in schizophrenia: past, present and future.
Topics: Niacin; Phospholipids; Schizophrenia; Signal Transduction; Vasodilation | 1996 |
The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism.
Topics: Alprostadil; Brain Chemistry; Clozapine; Diabetes Complications; Dietary Fats; Dopamine; Double-Blin | 1992 |
Biochemistry of tryptophan in health and disease.
Topics: Animals; Appetite Regulation; Brain Chemistry; Depressive Disorder; Female; Hartnup Disease; Humans; | 1983 |
The biology of folate in depression: implications for nutritional hypotheses of the psychoses.
Topics: Anorexia Nervosa; Biogenic Amines; Brain; Depressive Disorder; Diet; Folic Acid; Folic Acid Deficien | 1986 |
Nicotinic acid and psychiatry.
Topics: Aged; Anxiety; Avitaminosis; Brain Diseases; Child; Child, Preschool; Clinical Trials as Topic; Deme | 1971 |
7 trials available for niacin and Schizophrenia
| Article | Year |
|---|---|
Niacin sensitivity and the arachidonic acid pathway in schizophrenia.
Topics: Adult; Anti-Inflammatory Agents; Arachidonic Acid; Dose-Response Relationship, Drug; Erucic Acids; F | 2010 |
Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls.
Topics: Administration, Oral; Adult; Female; Flushing; Galvanic Skin Response; Humans; Male; Niacin; Schizop | 2006 |
The use of nicotinic acid and pyridoxine in the treatment of schizophrenia.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1981 |
Membrane fatty acids, niacin flushing and clinical parameters.
Topics: Adult; Antipsychotic Agents; Arachidonic Acids; Capsules; Cell Membrane; Clozapine; Dietary Fats, Un | 1996 |
The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism.
Topics: Alprostadil; Brain Chemistry; Clozapine; Diabetes Complications; Dietary Fats; Dopamine; Double-Blin | 1992 |
Nicotinic acid in the treatment of schizophrenias. Practical and theoretical considerations.
Topics: Adrenochrome; Antipsychotic Agents; Ascorbic Acid; Clinical Trials as Topic; Drug Evaluation; Drug T | 1975 |
Nicotinic acid and psychiatry.
Topics: Aged; Anxiety; Avitaminosis; Brain Diseases; Child; Child, Preschool; Clinical Trials as Topic; Deme | 1971 |
80 other studies available for niacin and Schizophrenia
| Article | Year |
|---|---|
Replication of the abnormal niacin response in first episode psychosis measured using laser Doppler flowmeter.
Topics: Flowmeters; Humans; Lasers; Niacin; Psychotic Disorders; Schizophrenia | 2022 |
Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route
Topics: Humans; Niacin; Retrospective Studies; Schizophrenia | 2023 |
Could a gene-environment interaction between NAPRT1 risk allele and pre-natal niacin deficiency explain 4 medical mysteries of schizophrenia research?
Topics: Alleles; Gene-Environment Interaction; Humans; Niacin; Schizophrenia | 2020 |
An association between niacin skin flush response and plasma triglyceride levels in patients with schizophrenia.
Topics: Adult; Blood Glucose; Cholesterol; Cohort Studies; Female; Flushing; Humans; Male; Middle Aged; Niac | 2020 |
Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker.
Topics: Biomarkers; Case-Control Studies; Humans; Mood Disorders; Niacin; Schizophrenia | 2021 |
A potential objective marker in first-episode schizophrenia based on abnormal niacin response.
Topics: Biomarkers; Flushing; Humans; Niacin; Psychotic Disorders; Schizophrenia; Skin | 2022 |
Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea.
Topics: Adolescent; Adult; Ascorbic Acid; Case-Control Studies; Diet; Dietary Carbohydrates; Dietary Fats; D | 2021 |
Low dietary intake of n-3 fatty acids, niacin, folate, and vitamin C in Korean patients with schizophrenia and the development of dietary guidelines for schizophrenia.
Topics: Adult; Ascorbic Acid; Diet; Fatty Acids, Omega-3; Feeding Behavior; Female; Folic Acid; Humans; Male | 2017 |
Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.
Topics: Adult; Biomarkers; China; Erythema; Female; Humans; Male; Mood Disorders; Niacin; Schizophrenia; Sen | 2018 |
A Unique Genome-wide Association Study of a Psychiatric Disorder From India.
Topics: Genome-Wide Association Study; Humans; India; Multifactorial Inheritance; Niacin; Schizophrenia | 2019 |
Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study.
Topics: Adult; Animals; Case-Control Studies; Cell Line, Tumor; Chromosomes, Human, Pair 8; Disease Models, | 2019 |
Cognition and autonomic function in schizophrenia: inferior cognitive test performance in electrodermal and niacin skin flush non-responders.
Topics: Adult; Cognition; Cognition Disorders; Female; Galvanic Skin Response; Humans; Male; Neuropsychologi | 2015 |
Polymorphisms in PLA2G6 and PLA2G4C genes for calcium-independent phospholipase A2 do not contribute to attenuated niacin skin flush response in schizophrenia patients.
Topics: Adult; Croatia; Female; Flushing; Group IV Phospholipases A2; Group VI Phospholipases A2; Humans; Ma | 2015 |
Niacin supplement in schizophrenia: Hit two birds with one stone.
Topics: Humans; Niacin; Schizophrenia; Vitamin B Complex | 2015 |
Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia.
Topics: Adult; Bipolar Disorder; Endophenotypes; Female; Flushing; Humans; Laser-Doppler Flowmetry; Male; Mi | 2016 |
The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia.
Topics: Adult; Bipolar Disorder; Blotting, Western; Brain; Female; Gene Expression; Gyrus Cinguli; Humans; M | 2008 |
Hallucinogens as hard science: the adrenochrome hypothesis for the biogenesis of schizophrenia.
Topics: Adrenochrome; Hallucinogens; History, 20th Century; Humans; Lysergic Acid Diethylamide; Models, Psyc | 2010 |
A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia.
Topics: Adult; Female; Flushing; Genetic Linkage; Genetic Loci; Genetic Predisposition to Disease; Genome-Wi | 2013 |
Niacin subsensitivity is associated with functional impairment in schizophrenia.
Topics: Administration, Cutaneous; Adult; Dose-Response Relationship, Drug; Female; Flushing; Humans; Laser- | 2012 |
The impact of PLA2G4A and PTGS2 gene polymorphisms, and red blood cell PUFAs deficit on niacin skin flush response in schizophrenia patients.
Topics: Adult; Cyclooxygenase 2; Erythrocytes; Fatty Acids, Unsaturated; Female; Genotype; Genotyping Techni | 2013 |
Increased phospholipase A2 activity in schizophrenia with absent response to niacin.
Topics: Adult; Antipsychotic Agents; Female; Fluorometry; Humans; Male; Niacin; Phospholipases A; Phospholip | 2003 |
The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Flushing; Hemodynamics; Human | 2003 |
[Relation between schizophrenia and tuberculosis in therapy with a new anti-tuberculous chemical agent: isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Rorschach Test; Schizophrenia; Tuberculosis; Tuberculosis, Pulmo | 1953 |
[Use of isonicotinic acid hydrazide in nontuberculous mental patients].
Topics: Isoniazid; Mentally Ill Persons; Niacin; Nicotinic Acids; Schizophrenia | 1953 |
Isoniazid in treatment of the chronic schizophrenic patient.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Schizophrenia | 1954 |
[Treatment of chronic schizophrenia by a combination of electroshock, pantothenic acid and nicotinamide].
Topics: Convulsive Therapy; Electroconvulsive Therapy; Electroshock; Niacin; Niacinamide; Nicotinic Acids; P | 1954 |
Effect of isonicotinic acid hydrazide in tuberculous and nontuberculous schizophrenics.
Topics: Isoniazid; Niacin; Nicotinic Acids; Schizophrenia; Tuberculosis | 1954 |
Schizophreniclike psychotic reactions with administration of isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Psychotic Disorders; Schizophrenia; Tuberculosis | 1954 |
Isonicotinic acid hydrazide in the treatment of schizophrenia.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Schizophrenia | 1954 |
[Use of intrathecal isoniazid in schizophrenia].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Schizophrenia | 1955 |
[Use of intrathecal isoniazid in schizophrenia].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Schizophrenia | 1955 |
The hypocholesterolemic effect of nicotinic acid and its relationship to the autonomic nervous system.
Topics: Autonomic Nervous System; Cholesterol; Humans; Lipid Metabolism Disorders; Niacin; Nicotinic Acids; | 1957 |
Tryptophan-nicotinic acid metabolism in schizophrenia.
Topics: Biochemical Phenomena; Niacin; Schizophrenia; Tryptophan | 1958 |
Iproniazid phosphate in the treatment of the chronic hospitalized schizophrenic.
Topics: Iproniazid; Niacin; Nicotinic Acids; Phosphates; Schizophrenia | 1958 |
Observations of schizophrenic patients after iproniazid and tryptophan.
Topics: Iproniazid; Isomerism; Niacin; Nicotinic Acids; Schizophrenia; Tryptophan | 1958 |
Iproniazid treatment and metabolism of labeled epinephrine in schizophrenics.
Topics: Biochemical Phenomena; Epinephrine; Humans; Iproniazid; Isomerism; Niacin; Nicotinic Acids; Schizoph | 1958 |
Effects of iproniazid on chronic and regressed schizophrenics.
Topics: Iproniazid; Isomerism; Niacin; Nicotinic Acids; Schizophrenia | 1959 |
Marsilid and pacatal in the treatment of depressive schizophrenic reactions.
Topics: Autonomic Agents; Depression; Depressive Disorder; Niacin; Nicotinic Acids; Psychotic Disorders; Sch | 1959 |
[Sleep and the vascular action of nicotinic acid].
Topics: Blood Vessels; Humans; Niacin; Nicotinic Acids; Schizophrenia; Schizophrenic Psychology; Sleep | 1959 |
The use of triflupromazine with iproniazid for the treatment of chronic schizophrenic patients.
Topics: Humans; Iproniazid; Niacin; Nicotinic Acids; Phenothiazines; Schizophrenia; Triflupromazine | 1959 |
The effects of nicotinic acid, nicotinamide, and placebo on the chronic schizophrenic.
Topics: Humans; Niacin; Niacinamide; Nicotinic Acids; Schizophrenia | 1960 |
Nicotinamide in the treatment of schizophrenia.
Topics: Humans; Niacin; Niacinamide; Nicotinic Acids; Schizophrenia | 1962 |
Nicotinic acid: an adjunct in the treatment of schizophrenia.
Topics: Humans; Niacin; Nicotinic Acids; Schizophrenia | 1963 |
MALVARIA: A NEW PSYCHIATRIC DISEASE.
Topics: Alcoholism; Antidepressive Agents; Antisocial Personality Disorder; Child; Chromatography; Classific | 1963 |
[CERTAIN CLINICO-PATHOPHYSIOLOGICAL CHARACTERISTICS OF THE SIMPLE FORM OF SCHIZOPHRENIA].
Topics: Cholinesterases; Clinical Enzyme Tests; Conditioning, Classical; Muscles; Niacin; Nicotinic Acids; P | 1964 |
THE USE OF NICOTINAMIDE TEST DOSE IN THE ASSESSMENT OF PSYCHOTROPIC DRUGS IN SCHIZOPHRENIC PATIENTS.
Topics: Biomedical Research; Chlordiazepoxide; Chlorpromazine; Humans; Imipramine; Lactose; Niacin; Niacinam | 1964 |
[THE EFFECT OF THIAMINE ON THE ORIENTATION REFLEX AND THE NICOTINIC ACID REACTION IN SCHIZOPHRENICS. I].
Topics: Body Temperature; Niacin; Nicotinic Acids; Orientation; Reflex; Schizophrenia; Skin; Thiamine; Vasom | 1964 |
[THE EFFECT OF THIAMINE ON THE ELECTROSHOCK-INDUCED CHANGES OF THE ORIENTATION REFLEX AND OF THE NICOTINIC ACID REACTION IN SCHIZOPHRENICS. II].
Topics: Body Temperature; Convulsive Therapy; Electroconvulsive Therapy; Electroshock; Niacin; Nicotinic Aci | 1964 |
TREATMENT OF SCHIZOPHRENIA WITH NICOTINIC ACID. A TEN YEAR FOLLOW-UP.
Topics: Adolescent; Biomedical Research; Drug Therapy; Electroconvulsive Therapy; Follow-Up Studies; Hospita | 1964 |
[ATTEMPTS OF TREATMENT OF SCHIZOPHRENIA WITH ANTIMETABOLITES].
Topics: Antimetabolites; Drug Therapy; Humans; Niacin; Niacinamide; Schizophrenia; Triethylenemelamine | 1964 |
TREATMENT OF ORGANIC PSYCHOSIS WITH NICOTINIC ACID. (A SINGLE CASE).
Topics: Ascorbic Acid; Brain; Brain Damage, Chronic; Carcinoma, Bronchogenic; Dementia; Diagnosis, Different | 1965 |
Nicotinic acid therapy and the chronic schizophrenic.
Topics: Isomerism; Niacin; Nicotinic Acids; Schizophrenia | 1955 |
[The effect of nicotinic acid on the temperature of the skin of patients with schizophrenia in different states].
Topics: Body Temperature; Humans; Niacin; Nicotinic Acids; Schizophrenia; Skin; Temperature | 1961 |
Massive niacin treatment in schizophrenia. Review of a nine-year study.
Topics: Niacin; Nicotinic Acids; Schizophrenia | 1962 |
Phospholipid and eicosanoid signaling disturbances in schizophrenia.
Topics: Calcium; Eicosanoids; Humans; Niacin; Phospholipases A; Phospholipases A2; Phospholipids; Schizophre | 2003 |
Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.
Topics: Acute Disease; Adult; Case-Control Studies; Female; Flushing; Humans; Male; Niacin; Nicotinic Acids; | 2005 |
Treatment advice on the internet leads to a life-threatening adverse reaction: hypotension associated with Niacin overdose.
Topics: Administration, Oral; Antipsychotic Agents; Drug Overdose; Humans; Hypolipidemic Agents; Hypotension | 2006 |
Niacin skin flushing in schizophrenic and depressed patients and healthy controls.
Topics: Adult; Depressive Disorder; Diagnosis, Differential; Female; Flushing; Humans; Male; Middle Aged; Ni | 2006 |
Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives.
Topics: Administration, Cutaneous; Adult; Aged; Dose-Response Relationship, Drug; Female; Flushing; Genetic | 2007 |
Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.
Topics: Adult; Arachidonic Acids; Biomarkers; Brain; Cannabinoids; Cross-Sectional Studies; Dronabinol; Drug | 2007 |
Absent response to niacin skin patch is specific to schizophrenia and independent of smoking.
Topics: Administration, Cutaneous; Adult; Bipolar Disorder; Female; Flushing; Humans; Male; Niacin; Schizoph | 2007 |
Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy study.
Topics: Adult; Cerebral Cortex; Flushing; Humans; Magnetic Resonance Imaging; Male; Niacin; Phosphates; Schi | 2007 |
Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia.
Topics: Adolescent; Adult; Biomarkers; Child; Flushing; Humans; Microscopy, Interference; Niacin; Phenotype; | 2007 |
Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Coffee; Drinking Behavior; Female; Flushi | 2009 |
A family-based study of genetic association of the PTGDS gene with schizophrenia in a Chinese population.
Topics: Adolescent; Adult; China; Female; Flushing; Gene Frequency; Humans; Intramolecular Oxidoreductases; | 2008 |
Acanthosis nigricans and nicotinic acid.
Topics: Acanthosis Nigricans; Adult; Humans; Male; Niacin; Nicotinic Acids; Schizophrenia | 1981 |
The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Female; Humans; Male; Membrane Potentials; Middle Aged; N | 1997 |
Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia.
Topics: Adult; Antipsychotic Agents; Arachidonic Acid; Calcium; Calmodulin; Chlorpromazine; Enzyme Activatio | 1999 |
Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics.
Topics: Evoked Potentials, Auditory; Flushing; Humans; Niacin; Parents; Perceptual Disorders; Schizophrenia | 1999 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; | 2001 |
A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia.
Topics: Adult; Deficiency Diseases; Fatty Acids; Female; Humans; Male; Niacin; Reference Values; Schizophren | 2002 |
A case of drug-drug interaction involving clozapine.
Topics: Adult; Ascorbic Acid; Clozapine; Drug Eruptions; Drug Interactions; Humans; Male; Niacin; Schizophre | 1991 |
Niacin test in schizophrenia and affective illness.
Topics: Adolescent; Adult; Female; Flushing; Humans; Infusions, Intravenous; Male; Middle Aged; Niacin; Schi | 1991 |
Niacin skin flush is not diagnostic of schizophrenia.
Topics: Administration, Oral; Adult; Female; Flushing; Humans; Male; Niacin; Prostaglandins E; Schizophrenia | 1986 |
Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics.
Topics: Adult; Alcoholism; Flushing; Humans; Male; Niacin; Prostaglandins E; Schizophrenia; Skin Temperature | 1986 |
Pellagra With Casal Necklace Causing Secondary Schizophrenia With Capgras Syndrome in a Homeless Man.
Topics: Capgras Syndrome; Delusions; Humans; Ill-Housed Persons; Male; Pellagra; Schizophrenia | 2022 |
The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra.
Topics: Adult; Agoraphobia; Bipolar Disorder; Fatty Acids, Essential; Fatty Acids, Unsaturated; Female; Huma | 1981 |
Extra nutrients and mental illness.
Topics: Fatty Acids, Essential; Fatty Acids, Unsaturated; Humans; Pellagra; Schizophrenia | 1981 |
Pellagra and mental disturbance.
Topics: Animals; Brain; Diet; Hartnup Disease; Humans; Mental Disorders; Nicotinic Acids; Pellagra; Pyridoxi | 1978 |
Psychiatric manifestation in pellagra.
Topics: Adolescent; Adult; Anxiety; Child; Depression; Female; Humans; Male; Mental Disorders; Middle Aged; | 1972 |